50,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by Seven Grand Managers LLC

Seven Grand Managers LLC purchased a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $3,478,000. Seven Grand Managers LLC owned approximately 0.08% of Structure Therapeutics at the end of the most recent quarter.

Several other large investors have also made changes to their positions in GPCR. Geode Capital Management LLC boosted its position in shares of Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after acquiring an additional 8,444 shares in the last quarter. Invesco Ltd. boosted its position in shares of Structure Therapeutics by 7.6% during the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after acquiring an additional 30,162 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Structure Therapeutics by 474.9% during the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after acquiring an additional 145,434 shares in the last quarter. Jump Financial LLC boosted its position in shares of Structure Therapeutics by 105.9% during the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock worth $1,311,000 after acquiring an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Structure Therapeutics during the 2nd quarter worth approximately $3,480,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on GPCR. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Citizens Jmp reduced their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $109.25.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $39.54 on Thursday. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -45.45 and a beta of -1.31. The firm has a 50 day simple moving average of $45.83 and a 200 day simple moving average of $56.95. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. As a group, analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.29 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.